Table 2: Results of hepatotoxicity and treatment with gefitinib and erlotinib.

CaseWorst grade of gefitinib-induced hepatotoxicityPeak AST/ALT levels by gefitinib-induced hepatotoxicity (mg/dL)Time to gefitinib-induced hepatotoxicity (days)Response by gefitinibDuration of treatment with gefitinib (days)Retreatment with gefitinibInitial dose of erlotinib (mg)Worst grade of erlotinib-induced hepatotoxicityPeak AST/ALT levels by erlotinib-induced hepatotoxicity (mg/dL)Response by erlotinibDuration of treatment with erlotinib (days)

1263/155 22 PR 47 decreaseda  100     2 46/85 PR    159
23159/280 175 PR 189 decreaseda  150     0 22/21 SD    92
32128/197 42 PR 42 no  100     0 23/31 SD    184
43 89/263 53 PR 204 decreaseda  100     1 70/62 SD    116
53426/533 55 PR 167 decreaseda  100     1 71/45 SD    360
63252/252 191 PR 191 no  100     0 17/28 SD    56
73231/342 35 PR 58 decreaseda  75     0 18/22 PR    304
8 262/113 50 SD 50 no  75     0 23/30 SD    412

Abbreviations: AST: aspartate aminotransferase; ALT: alanine aminotransferase; PR: partial response; SD: stable disease.
aRetreatment with decreased amount of gefitinib.